Recruiting NCT05479305

Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies

No phase Interventional Penetrating Ulcer of Aorta Aneurysm Aortic Type B Aortic Dissection Residual Dissection After Type A Repair

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: The Valiant Captivia Stent Graft.
Who it may be relevant to: Registry conditions: Penetrating Ulcer of Aorta, Aneurysm Aortic, Type B Aortic Dissection, Residual Dissection After Type A Repair. Basic parameters: from 18 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: France
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft. Clinical utility measures throughout the procedure and until discharge will be assessed

Detailed description

Prospective, single-arm, non-randomised, multicenter, investigator initiated clinical study evaluating subjects implanted with The Valiant Captivia physician fenestrated stent graft for the treatment of aneurysms/penetrating ulcers, Type B aortic dissections or residual dissection after Type A repair, of the aortic arch and the descending thoracic aorta which are candidates for revascularisation of all three supra-aortic vessels (BT (brachiocephalic trunk) , LCCA (left Common Carotid artery), LSA (Left Subclavian Artery)

Interventions

Device The Valiant Captivia Stent Graft
Aortic arch/Descending aorta Repair

Primary outcome measures

Primary Safety Endpoints: [Time frame: 30 days]
Primary Effectiveness Endpoints: [Time frame: 30 days]

Secondary outcome measures (12)

Intra/periprocedural through Discharge Clinical Utility Measures 1 [Time frame: 0 to 30 days]
Intra/periprocedural through Discharge Clinical Utility Measures 2 [Time frame: 0 to 30 days]
Intra/periprocedural through Discharge Clinical Utility Measures 3 [Time frame: 0 to 30 days]
Intra/periprocedural through Discharge Clinical Utility Measures 4 [Time frame: 0 to 30 days]
Intra/periprocedural through Discharge Clinical Utility Measures 5 [Time frame: 0 to 30 days]
Intra/periprocedural through Discharge Clinical Utility Measures 6 [Time frame: 0 to 30 days]
Intra/periprocedural through Discharge Clinical Utility Measures 7 [Time frame: 0 to 30 days]
Major adverse event [Time frame: Up to 3 years]
Secondary endovascular procedures [Time frame: Up to 3 years]
Secondary endovascular procedures for primary device failures [Time frame: Up to 3 years]
Other [Time frame: Up to 3 years]
For TBAD, these additional observations will be evaluated [Time frame: 0 to 30 days]

Eligibility criteria

Inclusion criteria

TAA/PAU (Thoracic Aortic Aneurysms and Penetrating Ulcers):

Subject is at least 18 years of age.
Subject understands and has signed an Informed Consent approved by the Sponsor for this study.
Subject must be considered a candidate for revascularisation of BT, LCCA and LSA.
Subject must be able to tolerate surgical revascularisation of BT, LCCA and LSA.
Subject has a TAA/PAU which is:

a fusiform aneurysm with a diameter of ≥ 5.5 cm OR is > 2 times the diameter of the non-aneurysmal thoracic aorta; AND/OR
a saccular aneurysm or PAU (ulcer defined as ≥ 10 mm in depth and 20 mm in diameter, or symptomatic)
Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm
Subject has no thrombus in the proximal neck
Subject has a non-diseased aortic diameter between 25 mm and 42 mm and max diameter of the ascending aorta is ≤ 40 mm
Subject has a non-diseased LSA which is eligible for stent-grafting
Subject has sufficient landing zone within the LSA to accommodate the stent-graft without occlusion of any significant vessels
Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories.
Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft
Subject is affiliated with the social security system

Inclusion criteria

TBAD(Type B Dissections) and Residual dissection after Type A repair:

Subject is at least 18 years of age.
Subject understands and has signed an Informed Consent approved by the Sponsor for this study.
a) Subject has a degenerative aortic arch aneurysm which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And/or b) Subject has a complicated TBAD (acute, subacute or chronic) which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And/or c) Subject has a complicated residual dissection after replacement of the ascending aorta for type A aortic dissection which will require coverage of the LSA and extension of the proximal seal zone to zone 0
Subject has a healthy, non-diseased (without thrombus) aortic proximal seal zone of at least 20 mm
Subject has a healthy, non-diseased (without thrombus) aortic distal seal zone of at least 20 mm
Subject has a maximum diameter of the distal ascending aorta just above the BT of 40 mm
Subject has a non-diseased aortic diameter between 28 mm to 42 mm and the ascending aorta ≤ 40 m
Subject has a no atheromatous lesions int the arch and the BT, LCCA and LSA
Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories
Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft
Subject is affiliated with the social security system

Exclusion criteria

(Thoracic Aortic Aneurysms and Penetrating Ulcers, TAA/PAU):

Subject has an aneurysmal, tortuous, or atherosclerotic LSA.
Subject has an aneurysmal, tortuous, or atherosclerotic LCCA.
Subject has an aneurysmal, tortuous, or atherosclerotic BT.
Subject has an ascending aorta diameter > 40 mm
Subject has thrombus in the proximal neck
Subject has an emergent need of treatment of the aortic pathology
Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites
Subject has circumferential calcification in the common femoral or external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned.
Subject has an aortic atheroma classified as grade IV or grade V.
Subject has had previous endovascular repair of the ascending
Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise sealing of the device.
Subject is pregnant
Subject has a known allergy or intolerance to the device components.
Subject is in acute renal failure
Subject has a body habitus which prevents adequate visualisation of the aorta.
Subject has coronary artery disease with unstable angina and who has not received treatment.
Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration).
Subject has active systemic infection and/or a mycotic aneurysm.
Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study.
Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures.
Subject has a life expectancy of less than 2 years year.
Subject requires treatment of an infrarenal aneurysm at the time of the implantation.
Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device.
Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.
Subject has had a cerebral vascular accident (CVA) within 3 months.
Subject has had a myocardial infarction (MI) within 3 months.
Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment

Exclusion criteria

(Type B Dissections, TBAD and residual dissection after Type A repair):

Subject has an aneurysmal, tortuous, or atherosclerotic LCCA.
Subject has an aneurysmal, tortuous, or atherosclerotic LSA.
Subject has an aneurysmal, tortuous, or atherosclerotic BT.
Subject has a dissected BT and or LCCA
Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites.
Subject has circumferential calcification in the common femoral artery, external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned.
Subject has an aortic atheroma classified as grade IV or grade V.
Subject has had previous endovascular repair of the ascending, arch
Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal sealing sites that would compromise seal of the device
Subject is pregnant
Subject has a known allergy or intolerance to the device components
Subject is in acute renal failure
Subject has a body habitus which prevents adequate visualisation of the aorta.
Subject has coronary artery disease with unstable angina and who has not received treatment.
Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration).
Subject has active systemic infection and/or a mycotic aneurysm.
Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observationsof this study
Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures.
Subject has a life expectancy of less than 2 years.
Subject requires treatment of an infrarenal aneurysm at the time of the implantation.
Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device.
Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.
Subject has had a cerebral vascular accident (CVA) within 3 months.
Subject has had a myocardial infarction (MI) within 3 months.
Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation: N/A
Model: Single group
Masking: Open label
Primary purpose: Treatment

Study locations

France · 4 centers

CH de Brest — Brest
Hôpital Louis Pradel — Bron
CHU de Montpellier — Montpellier
CH d'Orléans — Orléans

Identifiers

NCT: NCT05479305 · EVERGREEN

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗